Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue.

Détails

ID Serval
serval:BIB_F89B0401188B
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue.
Périodique
Diabetes
Auteur(s)
Galmozzi A., Mitro N., Ferrari A., Gers E., Gilardi F., Godio C., Cermenati G., Gualerzi A., Donetti E., Rotili D., Valente S., Guerrini U., Caruso D., Mai A., Saez E., De Fabiani E., Crestani M.
ISSN
1939-327X (Electronic)
ISSN-L
0012-1797
Statut éditorial
Publié
Date de publication
2013
Volume
62
Numéro
3
Pages
732-742
Langue
anglais
Résumé
Chromatin modifications are sensitive to environmental and nutritional stimuli. Abnormalities in epigenetic regulation are associated with metabolic disorders such as obesity and diabetes that are often linked with defects in oxidative metabolism. Here, we evaluated the potential of class-specific synthetic inhibitors of histone deacetylases (HDACs), central chromatin-remodeling enzymes, to ameliorate metabolic dysfunction. Cultured myotubes and primary brown adipocytes treated with a class I-specific HDAC inhibitor showed higher expression of Pgc-1α, increased mitochondrial biogenesis, and augmented oxygen consumption. Treatment of obese diabetic mice with a class I- but not a class II-selective HDAC inhibitor enhanced oxidative metabolism in skeletal muscle and adipose tissue and promoted energy expenditure, thus reducing body weight and glucose and insulin levels. These effects can be ascribed to increased Pgc-1α action in skeletal muscle and enhanced PPARγ/PGC-1α signaling in adipose tissue. In vivo ChIP experiments indicated that inhibition of HDAC3 may account for the beneficial effect of the class I-selective HDAC inhibitor. These results suggest that class I HDAC inhibitors may provide a pharmacologic approach to treating type 2 diabetes.
Mots-clé
Adipose Tissue/cytology, Adipose Tissue/drug effects, Animals, Anti-Obesity Agents/pharmacology, Anti-Obesity Agents/therapeutic use, Cell Line, Cells, Cultured, Diabetes Mellitus, Type 2/complications, Diabetes Mellitus, Type 2/drug therapy, Energy Metabolism/drug effects, Gene Expression Regulation/drug effects, Histone Deacetylase 1/antagonists & inhibitors, Histone Deacetylase 1/metabolism, Histone Deacetylase 2/antagonists & inhibitors, Histone Deacetylase 2/metabolism, Histone Deacetylase Inhibitors/pharmacology, Histone Deacetylase Inhibitors/therapeutic use, Hypoglycemic Agents/pharmacology, Hypoglycemic Agents/therapeutic use, Male, Mice, Mice, Mutant Strains, Mitochondria, Muscle/drug effects, Mitochondria, Muscle/metabolism, Molecular Targeted Therapy, Muscle, Skeletal/drug effects, Muscle, Skeletal/metabolism, Obesity/complications, Obesity/drug therapy, Random Allocation
Pubmed
Web of science
Création de la notice
15/02/2015 22:43
Dernière modification de la notice
03/03/2018 22:52
Données d'usage